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Background: Traditional Indian Ayurvedic medicine uses complex treatment approaches, including manual
therapies, lifestyle and nutritional advice, dietary supplements, medication, yoga, and purification techniques.
Ayurvedic strategies are often used to treat osteoarthritis (OA) of the knee; however, no systematic data are
available on their effectiveness in comparison with standard care. The aim of this study is to evaluate the
effectiveness of complex Ayurvedic treatment in comparison with conventional methods of treating OA symptoms
in patients with knee osteoarthritis.
Methods and design: In a prospective, multicenter, randomized controlled trial, 150 patients between 40 and 70
years, diagnosed with osteoarthritis of the knee, following American College of Rheumatology criteria and an
average pain intensity of ≥40 mm on a 100 mm visual analog scale in the affected knee at baseline will be
randomized into two groups. In the Ayurveda group, treatment will include tailored combinations of manual
treatments, massages, dietary and lifestyle advice, consideration of selected foods, nutritional supplements, yoga
posture advice, and knee massage. Patients in the conventional group will receive self-care advice, pain medication,
weight-loss advice (if overweight), and physiotherapy following current international guidelines. Both groups will
receive 15 treatment sessions over 12 weeks. Outcomes will be evaluated after 6 and 12 weeks and 6 and 12
months. The primary endpoint is a change in the score on the Western Ontario and McMaster University
Osteoarthritis Index (WOMAC) after 12 weeks. Secondary outcome measurements will use WOMAC subscales, a pain
disability index, a visual analog scale for pain and sleep quality, a pain experience scale, a quality-of-life index, a
profile of mood states, and Likert scales for patient satisfaction, patient diaries, and safety. Using an adapted PRECIS
scale, the trial was identified as lying mainly in the middle of the efficacy-effectiveness continuum.
Discussion: This trial is the first to compare the effectiveness of a complex Ayurvedic intervention with a complex
conventional intervention in a Western medical setting in patients with knee osteoarthritis. During the trial design, aspects
of efficacy and effectiveness were discussed. The resulting design is a compromise between rigor and pragmatism.
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Among chronic diseases, osteoarthritis (OA) is becoming
increasingly significant and is responsible for a major part
of the disease burden, work disability, and healthcare costs
in Germany, Europe, and worldwide [1]. The guidelines for
treatment of OA of the knee from the National Institute
for Health and Clinical Excellence, the American College
of Rheumatology and the European League Against
Rheumatism recommend nondrug treatments, including
the education of patients, social support, physical exercise,
and weight loss [2-5]. Nonsteroidal anti-inflammatory
drugs (NSAIDs) are still used as the initial treatment in pri-
mary care [6,7]; however, they are associated with a num-
ber of side effects, such as upper gastrointestinal bleeding
and renal failure [8], as well as myocardial infarction and
stroke, especially in the COX-2 inhibitor category [9].
Patients with osteoarthritis as pars pro toto for chronic dis-
eases often seek complementary and alternative medicine
(CAM) therapies [10].
Ayurveda, is the most prominent medical system of trad-
itional Indian medicine, and is commonly used throughout
South Asia. It has been practiced there as a whole system
of medicine for more than 2000 years. Ayurveda is one
of the oldest systems of medicine worldwide and is
acknowledged as a medical science by the World Health
Organization [11-13]. In India alone, more than 400,000
Ayurvedic physicians are officially registered; Ayurveda
can be studied and applied systematically at more than
250 government-accredited universities or colleges [14].
Ayurveda is also playing an increasing role in European
and North America, since its broad introduction in
Western countries in the 1980s. At present, it is one of the
fastest-growing CAM therapies worldwide [12,15-22].
Ayurveda claims to be effective in treating chronic diseases
of the musculoskeletal system [23-25]. It uses complex and
individually tailored interventions, including manual ther-
apies, lifestyle and nutritional advice, dietary supplements,
medication, yoga, and purification measures [25].
Ayurveda has its own sophisticated diagnostic system;
OA generally belongs to a cluster of diseases in which the
Ayurvedic principle of kinetic energy, ‘vata’, prevails. Thus,
a reduction and regulation of the aggravated principle of
kinetic force stands to the fore of a complex Ayurvedic
treatment approach for OA of the knee [26]. However, the
conventional diagnosis ‘osteoarthritis of the knee’ cannot
be directly translated into the Ayurvedic diagnostic sys-
tem. As an approximation, the Ayurvedic term ‘[janu-]
sandhi-gata-vata’ (literal translation from Sanskrit: ‘vata is
seated [has moved] in [into] the [knee-] joint’) is most
commonly used by the Ayurvedic fraternity. However,
sometimes other Ayurvedic diagnoses may also apply (for
example, khuda-vata, ama-vata, jirna-vata, vata-rakta).
According to Ayurveda, the causes of OA are most often
attributed to improper diet, unfavorable life style, trauma,aging processes, and constitutional predispositions. This
favors an aggravation of the principle of vata, responsible
for all movement, musculoskeletal, and locomotor func-
tions in the body. The aggravated principle of vata brings
dryness (rukshata), lightness (laghutva), porosity (saushirya),
and coarseness (kharatva) into the joints. Corresponding to
Ayurvedic models of pathogenesis, the disease is caused
when the aggravated principle of vata settles in the knee
joint and begins to destroy the structure and function of
the joint. The features seen in OA and sandhi-gata-vata are
similar. In the Ayurvedic disease-entity, pain in the knee
joint (sandhi-shula) is the main feature and can be accom-
panied by other features including swelling (shotha),
stiffness (stabdhata), crepitus (atopa) and difficulties
in performing proper functions of the knee joint
[23,24,27-29].
Most noticeably, Ayurveda and conventional Western
medicine are based on different sets of logical axioms. It
can be difficult to identify precise correspondences be-
tween related disease entities within these two systems of
disease classification [30-35]. Mean-value based medical
strategies are avoided in the constitution-based Ayurvedic
approach. Moreover, nomenclatures for disease entities
are seen to be of lower importance than nomenclatures
for ‘milieu interior changes’ in Ayurvedic medicine [25].
Besides symptom detection, Ayurvedic diagnosis in-
volves a general investigation into a broad spectrum of in-
ternal and external conditions, including physiological,
metabolic, kinetic, excretory and mental functions, life
style, food habits, social and other factors, all capable of
developing disharmonies within the patient’s mind-body
continuum. By inquiring into a patient’s history and inves-
tigations based on refined sense perception (palpation,
auscultation, percussion, inspection, and so on), these fac-
tors are analyzed and evaluated. Pathogenic disharmonies
are classified in terms of dynamic Ayurvedic principles,
which cannot be directly equated with modern entities
(and have to be explained in other ways, for example,
dosha, agni, srotas, dhatu, mala, ama). These principles
are found in distinct states and individual pathological
constellations and may result in specific symptoms. Fur-
thermore, healthy states and disease are seen as a con-
tinuum in Ayurveda. Diagnosis is believed to be the
definition of a snapshot within a constant flow of physio-
logical and pathophysiological factors. This enables the
Ayurvedic physician to treat a case without giving the
disease a name, by dealing with the aforementioned
principles [23].
As an example, osteoarthritis of the knee may be accom-
panied by (in Ayurveda) so-called ‘aggressive intermediate
metabolic products’ (ama), leading to systemic or local
joint pathologies, resembling, but not equating, features of
rheumatoid arthritis, other autoimmune conditions or
gout. Consequently, the Ayurvedic diagnosis may not be
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ama-derived situations (ama-vata) or the effects of a ‘hot-
acidic blood tissue’ (vata-rakta). However, in conventional
medicine, the diagnosis osteoarthritis of the knee would
remain the same in all three cases. Ultimately, an experi-
enced Ayurvedic physician would treat the principles of
vata, ama, or rakta, rather than a circumscribed diagnosis.
Summarized, standardized diagnosis and therapy are
avoided in constitutional Ayurvedic medicine; the overall
situation of the patient is analyzed, rather than merely the
disease [25].
There is some clinical evidence of the effects of
Ayurvedic therapies for OA that derives from a limited
amount of clinical studies, largely from South Asia
[26,36-70]. Most of these trials show limitations regarding
their trial designs or methodological transparency. How-
ever, Ayurveda is a whole medical system using complex
treatment approaches. In theory and practice, it is funda-
mentally based on constitutional axioms. Ayurveda
(alongside its somatic approaches) intentionally includes
mind-body and psychosomatic aspects in diagnosis and
therapy of all diseases. Complex treatments follow the the-
ory that the combination of different treatment elements
exerts synergistic effects and is relevant for the outcome
[71,72]. However, to date, no clinical study on OA has been
performed that has taken into account the multidimen-
sional approach of Ayurveda as a complex and whole med-
ical system. Another limitation of all previous randomized
controlled studies on Ayurveda is that they have focused
only on structural Western diagnoses and disease cogni-
tions without considering the fundamental principles of
the traditional Ayurvedic diagnostic approach.
As for Western countries, there are very limited
amounts of clinical data on single Ayurvedic interven-
tions (for example, leeches [73,74] and ginger extract
[75,76]) and no data for complex Ayurvedic treatment
of OA. To date it is unknown whether such a complex
treatment approach has a clinically relevant effect and
whether its effectiveness can exceed the effectiveness of
conventional standard care for OA. Moreover, it re-
mains unclear whether local and geographical aspects
influence the therapeutic outcome, for example, when
Ayurveda is being practiced outside its countries of
origin. Overall, there is a need for more evidence from
comparative studies in medicine [77], in order to assist
healthcare stakeholders in informed decision making.
This is also the case for traditional Indian medicine
as pars pro toto for CAM and is especially recommended
for the comparison of whole medical systems like Ayurveda
[78]. The generation and synthesis of evidence compar-
ing the benefit and harm of alternative methods to pre-
vent, diagnose, treat, and monitor a clinical condition
or to improve the delivery of care is called comparative-
effectiveness research [79].Our clinical hypothesis is that 12 weeks of complex
Ayurvedic treatment based on Ayurvedic diagnosis is more
effective than 12 weeks of conventional standard care in
the treatment of OA of the knee (based on the WOMAC
Index). The aim of this study is to compare and evaluate
the effectiveness (measured with the WOMAC Index) of a
complex individualized Ayurvedic treatment based on
Ayurvedic diagnosis in comparison with conventional
medical care for osteoarthritis of the knee following
current international treatment guidelines for patients with
OA of the knee.
Methods
Patients
We include patients who fulfill the following criteria: men
and women aged 40 to 70 years, who have OA of the knee,
as prediagnosed by a specialist (such as an orthopedic
specialist or surgeon or a radiologist) according to the
American College of Rheumatology criteria [3,80]. Radio-
logic changes of the knee in the images used by the spe-
cialist when diagnosing OA should be a Kellgren-Lawrence
score of at least grade 2 in X-ray [81,82] or a Recht grading
score of at least grade 2(a) in MRI [83-85]. The patients will
have reported a mean pain intensity in the affected knee
of ≥40 mm on a 100 mm visual analog scale over the 7 days
before baseline assessment, and provide written informed
consent.
Patients are excluded for the following criteria: the pain
in the knee is caused by congenital dysplasia of the af-
fected knee, rheumatoid arthritis, autoimmune diseases,
malignancies, knee surgery or knee-arthroscopy; the pa-
tient has been administered any chondroprotective drugs,
intra-articular injection into the affected knee joint or sys-
temic medication with corticosteroids during the preced-
ing 3 months; the patient has begun any new treatment
for OA during the previous 4 weeks (except analgesic
treatment with paracetamol or NSAIDs available over-
the-counter); the patient is pregnant or breastfeeding;
the patient has an acute mental disorder, a serious acute
organic disease, or a serious chronic comorbidity, or is
obese (at least WHO grade II); the patient has a blood co-
agulation disorder, or takes coagulation-inhibiting medica-
tion other than acetylsalicylic acid and clopidogrel; invasive
measures have been performed at the affected joint during
the previous 12 weeks or are planned for the following 12
month; or the patient is in the process of applying for pen-
sion or disability benefits. Furthermore, patients are ex-
cluded if they had any serious comorbidity that made it
impossible to participate in the trial interventions (for ex-
ample, heart failure NYHA IV).
Patients are recruited from the Immanuel Hospital
and Charité Medical University Berlin outpatient clinics.
In addition, patients are being informed about the trial
in media reports and advertisement in local newspapers.
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Charité University Medical Center (No. EA1/124/10) and
is conducted according to the common guidelines for clin-
ical trials (Declaration of Helsinki). The trial registration
number is NCT01225133. Informed consent is obtained
for all patients. The trial is in the recruitment phase.
Randomization
Patients are randomized to Ayurvedic or conventional
treatment in a 1:1 ratio on the basis of a stratified (strata
defined by study site) block-randomization (variable block
lengths). The study biometrician generated a randomization
list with SAS/STAT software (version 9.1, SAS Inc., Cary,
NC). The randomization list is stored by the data manager
on a secure database (Microsoft Office Access 2007), where
the randomization list is not accessible to any other staff
members or study physicians. After registration of the pa-
tient details in the secure database, the study nurse has to
click a button to perform randomization. Each patient can
be only registered and randomized once: the database does
not allow any patients details to be deleted.
Study design
In this prospective, multicenter, randomized controlled trial,
all patients included into the study receive an Ayurvedic
diagnosis before randomization. After randomization, pa-
tients in the Ayurveda group receive a complex individual-
ized Ayurvedic treatment tailored according to their
Ayurvedic diagnosis. Patients randomized into the conven-
tional treatment group will receive conventional medical
treatment following current guidelines (Figure 1). Because
all patients receive the Ayurveda diagnosis, we exclude
the context effects of this procedure from our results
(for further explanations on design aspects see [86]). The
treatment will be performed in two trial centers in
Berlin, Germany.
To improve the validity of the Ayurvedic diagnosis
within the trial, the first 30 patients recruited for theFigure 1 Trial design.trial were included in an embedded diagnostic trial (to be
reported elsewhere). After inclusion into the trial, they
were diagnosed by four independent Ayurvedic medical
specialists, each of whom documented an individualized
treatment plan for the patient with the help of a standard-
ized form. All assessment and treatment plans for the first
30 patients were discussed between the doctors until con-
sensus was reached for each patient. The results will be
reported elsewhere.
Outcomes
The primary outcome measure will be rated using the
Western Ontario and McMaster University Osteoarthritis
Index (WOMAC) after 12 weeks [87,88]. We used the 10-
point numeric rating scale, as described in the German
version, and normalized the results to a 100-point scale. If
the patient has bilateral OA of the knee and both knees
fulfill the eligibility criteria, the WOMAC Index is used
for the same knee throughout the whole study period; the
knee that affects the patient most at baseline. Secondary
outcome measures will be made using WOMAC subscales
(pain, function and stiffness), a pain disability index, a vis-
ual analog scale for pain and quality of sleep (0 to 100
mm), a pain experience scale, a quality-of-life index, a pro-
file of mood states, Likert scales for general health-related
patient satisfaction, and a patient diary for interventions
and co-interventions (medication, yoga or exercise, self-
applied massage, health services usage), and safety records
(adverse events, serious adverse events). Outcomes will be




The Ayurveda intervention is multimodal and follows the
principles of Ayurveda as a whole medical system. The
Ayurveda intervention was developed over 18 months in an
international consensus procedure including experienced
Figure 2 Ayurveda intervention.
Figure 3 Conventional treatment.
Witt et al. Trials 2013, 14:149 Page 5 of 10
http://www.trialsjournal.com/content/14/1/149Ayurveda experts from India, Germany, and Italy. In
addition, it was based on classical Ayurvedic literature
[23,24,27,28].
Treatment includes a tailored combination of manual
treatments and massages, nutritional advice, specific con-
sideration of selected food items and nutritional supple-
ments, general and specific lifestyle advice, yoga posture
advice for the knee and daily self-applied home knee mas-
sage. Patients receive 15 treatment sessions up to a max-
imum of 90 minutes each (Figure 2). To ensure the
highest treatment quality, the therapeutic regimes for the
first 30 patients were outlined independently by four
Ayurvedic medical experts and the patients received the
consensus-based therapy.
Conventional care group
Patients randomized into the control group receive con-
ventional standard care for osteoarthritis of the knee
according to the current international guidelines [4,89,90].
Conventional standard care treatment is provided by
orthopedic specialists, surgeons, physiotherapists, and oc-
cupational therapists. In Germany, OA is usually treated
by orthopedic specialists or surgeons, according to treat-
ment guidelines issued by the German Association of
Orthopedics.
The treatment (Figure 3) is individualized and includes
quadriceps muscle strengthening exercises, local physio-
therapy including manual therapy and friction massage,
occupational therapy, advice for individual knee exercise
(knee school), if a patient is overweight or obese dietary
advice for weight loss, if necessary administration of medi-
cation according to the current guidelines. Patients receive
15 sessions with a duration of 45 minutes.
Both groups
In both treatment groups, a maximum of 3g paraceta-
mol per day can be used as rescue medication. In case of
intolerance or unresponsiveness to paracetamol, topical
or oral NSAIDs can be used, on the advice of a study
physician (for example, diclofenac-sodium ointment
three times a day or oral ibuprofen up to a maximum
dose of 800 mg daily or equivalent. For safety reasons,
this dosage of oral NSAID was kept low.)
Selection and qualification of providers and treatment
context
In the Ayurveda group all involved medical doctors
had undergone either a regular university program for
Ayurveda in India (Indian experts) or at least 500 hours of
academic training in Ayurveda plus at least 2 years of con-
tinuous clinical experience with Ayurveda (European ex-
perts). All other involved Ayurvedic therapists require a
minimum of 2 years of continuous clinical experience in
their corresponding field of expertise (manual therapies,nutritional advice, lifestyle advice, knee yoga counseling).
To ensure the highest treatment quality, the therapeutic re-
gimes for the first 30 patients were outlined independently
by four Ayurvedic medical experts (all medical doctors)
and the patients received the consensus-based therapy.
This was assessed in an embedded diagnostic trial; the re-
sults will be presented elsewhere.
In the control group, the individual intervention is
prescribed by medical doctors with a specialized degree
in orthopedics, surgery, or physical medicine or by other
medical doctors working in orthopedics, orthopedic sur-
gery, or physical medicine under the direct guidance of a
specialist for orthopedics or orthopedic surgery. All
other involved therapists (physiotherapy, occupational
therapy) require a completed training in their field and a
minimum of 2 years of continuous clinical experience.
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hospital-affiliated centers for orthopedics, surgery, phys-
ical medicine, physiotherapy, or occupational therapy.
Statistics
This study is designed to have 80% power to detect a 10-
point improvement (change from baseline) on the
WOMAC Index after 12 weeks between both groups
(common standard deviation = 20, two-sided t-test α =
0.05). To achieve this, 64 patients per group are needed; to
take dropouts into account, 75 patients per group will be
included, resulting in a total of 150 patients.
The primary analysis population is the intention-to-treat
population, which includes all randomized patients, who
provided baseline data, regardless whether or not they ad-
here to the protocol or give a complete set of data.
The statistical hypotheses are:
H0: mean WOMAC Index (Ayurveda) = mean
WOMAC Index (conventional)
HA: mean WOMAC Index (Ayurveda) ≠ mean
WOMAC Index (conventional)
The primary outcome is a change in the score on the
WOMAC Index after 12 weeks. Missing data will be
multiply imputed by maximum-likelihood based regres-
sion methods. Overall, 20 complete datasets will be gener-
ated. Generalized linear mixed models will be fitted to
each of these datasets, including study centers as a ran-
dom effect, treatment group as a fixed factor, and the pa-
tient’s baseline WOMAC score as a linear covariate. The
20 concurring results (one for each copy of datasets) will
be adequately combined. Results will be presented as ad-
justed WOMAC means per group with 95% confidence
intervals and two-sided P value for the treatment group
comparison.
For sensitivity analysis, this statistical model will be ex-
tended to include the patients’ and physicians’ expecta-
tions as ordinal fixed factors to the generalized linear
mixed model.
Additional sensitivity analyses include the use of other
computation methods, calculation of results based on the
full analysis set (patients without missing WOMAC data
at week 12), and the inclusion of potential confounding
factors in the model in case of relevant baseline differences
between the treatment groups.
A detailed statistical analysis plan will be developed
before analyzing the data.
Positioning of the trial within the efficacy-effectiveness
continuum
It is essential to distinguish between ‘efficacy’ and ‘effect-
iveness’. ‘Efficacy’ refers to ‘the extent to which a specific
intervention is beneficial under ideal conditions’ [91].Many randomized controlled trials are efficacy trials, par-
ticularly those conducted for regulatory drug approval.
They aim to produce the expected result for an interven-
tion under carefully controlled conditions chosen to
maximize the likelihood of observing an effect, if it exists.
The trial population and setting of efficacy trials can differ
in important ways from the clinical settings in which the
interventions are likely to be used [92]. By contrast, ‘effect-
iveness’ is a measure of the extent to which an interven-
tion, when deployed in the field in routine circumstances,
does what it is intended to do for a specific population
[91] and therefore can often be more relevant to policy
evaluation and the healthcare decisions of providers
and patients. The pragmatic-explanatory continuum indi-
cator summary (PRECIS) tool [93] was used to guide the
design of the trial along ten dimensions of the efficacy-
effectiveness continuum. PRECIS was adapted rating the
items patients’ compliance and practitioners’ adherence
for both interventions separately, and deleting the
item primary analyses. Seven authors (CMW, Andreas
Michalsen, CK, Antonio Morandi, LK, SG, MM) independ-
ently carried out the first rating using a five-point scale
(1, maximum efficacy, displayed in the center of the figure;
five, maximum effectiveness, displayed at the edge of the
figure [94]). Results were displayed and harmonized in a
second rating. The trial is multidimensional and can be
seen to lie mainly in the middle of the efficacy-
effectiveness continuum (Figure 4). As shown in the figure,
the flexibility of both interventions (Ayurveda and conven-
tional care) is high and represents more the effectiveness
side of the trial, whereas follow-up intensity, practitioner
adherence, and patient compliance represent more the effi-
cacy side. This represents very well the efforts that have
been made during the trial-planning phase to produce a
trial that allows a patient-centered individualized treat-
ment, but at the same side tries to exclude some bias.
Discussion
This trial compares for the first time the effectiveness of a
complex Ayurvedic intervention with a complex conven-
tional intervention in a Western medical setting. Our aim
was to develop a high-quality study that compared both
medical systems ‘head-to-head’ and allows a complex tai-
lored intervention in both groups. Reviews of research
studies on Ayurvedic medicine so far reveal that the major-
ity of them are experimental, focusing on single herbs, for-
mulations, or therapies. A minority of existing Ayurveda
research is clinical, focused either on medication only or on
nonpharmacologic interventions, such as yoga. Most of
these trials have methodological limitations ([21,95]).
Recently, a change of this trend could be observed in a
randomized controlled trial on rheumatoid arthritis, suc-
cessfully demonstrating that the individualized Ayurvedic
treatment approach can be incorporated in a standard
Figure 4 Placement of the trial in the efficacy/effectiveness continuum (efficacy is towards the center, effectiveness towards the edge).
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cessful, even where more than one placebo preparation is
required [96,97]. However, although the work of Furst
et al. was of great importance for future randomized con-
trolled trial studies on other CAM disciplines [98], in par-
ticular on whole medical systems, it did not fully test the
multidimensional aspect of Ayurvedic therapy, since it in-
cluded the pharmacological dimension only. Overall,
Ayurveda has rarely been studied in its whole and multidi-
mensional perspective and in the manner in which it is ac-
tually being practiced.
The main challenge is to develop novel and innovative
clinical study protocols to evaluate whether Ayurveda and
its logic foundations are able to generate clinical evidence
in full accordance with modern research methodologies.
This will eventually allow the integration of traditional
medical knowledge into modern science-based medicine.
This clinical trial is the first attempt in this direction,
since it makes full use of the complex and multidimen-
sional therapeutic methodology of Ayurveda, individual-
ized according to the patient’s needs. Nevertheless, using
a trial design where neither patients nor providers or as-
sessors can be blinded introduces bias. Expectation is
discussed as one of the prominent mechanisms of the
placebo effect [99]; by controlling for patients’ expect-
ation in the statistical analyses, we try to reduce this
bias. Another limitation is that the consultation duration
between patients and providers differs in both interven-
tion groups. However, this reflects the usual care setting
of both medical systems. Reducing the consultation dur-
ation in the Ayurvedic group would not allow adequate
treatment while reducing the consultation duration in
the conventional group would introduce an artificial set-
ting. In usual care, those patients who do not respondwell to conventional treatment often become interested in
complementary medicine. This could have introduced a
bias towards Ayurveda. One method to reduce this bias
could have been to recruit only incident cases of OA of the
knee. However, this would have resulted in recruitment
problems and less generalizability of the results, because
patients usually seek complementary medicine treatments
after they have already had the disease for some time.
The Ayurvedic treatment was developed in a consensus
procedure with Indian and European Ayurveda experts.
The treatment protocol had to take into account German
standards of medical care and the availability of Ayurvedic
interventions in Germany. Because the Ayurveda treat-
ment was based on Ayurvedic diagnoses, a diagnostic val-
idation study was included to train the Ayurveda study
physician. To ensure high-quality personalized treatment
in the conventional group, the complex conventional
intervention was based on current treatment guidelines
for osteoarthritis of the knee and the final treatment
protocol was developed in a consensus procedure with
orthopedists and physiotherapists.
In the conventional treatment group, intra-articular cor-
ticosteroid injections were not part of the treatment
protocol, because in Germany many patients with osteo-
arthritis of the knee refuse this treatment. Furthermore,
medication dosage was adapted to reduce the risk of
gastrointestinal bleeding. Being aware that our approach
reduces the generalizability of the results to other coun-
tries, we excluded them with the aim of reducing selection
bias, to reduce the difference in the characteristics of those
who are selected for the study versus those who are not.
Although the study aimed to perform a ‘head-to-head’
comparison, for ethical reasons patients in the Ayurveda
group are allowed to take rescue pain medication. This
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determine whether Ayurveda is superior to conventional
treatment, instead of using a noninferiority or equiva-
lence approach. In the worst case, if both groups receive
similar amounts of pain medication, the main difference
between them would be in the different therapies offered
to the two groups. The conventional group receives 15
45-minute sessions of individualized therapy including
quadriceps muscle strengthening exercises, local physio-
therapy including manual therapy and friction massage,
occupational therapy, advice for individual knee exercise
(knee school), and, where a patient is overweight or obese,
dietary advice for weight loss. The Ayurveda treatment is
a tailored combination of manual treatments and mas-
sages, nutritional advice, specific consideration of selected
food items and nutritional supplements, general and spe-
cific lifestyle advice, yoga posture advice for the knee and
daily self-applied home knee massage, in 15 treatment
sessions lasting up to a maximum of 90 minutes each.
In designing the trial, aspects of efficacy and effective-
ness were discussed in depth; the resulting design is a
compromise between rigor and pragmatism. We decided
to apply several exclusion criteria to achieve a more
homogeneous study population, for two reasons: safety
and less variance in the outcomes. Although the treat-
ment protocol for both groups allows flexibility, having
only a very small number of centers trained in the diag-
nostic procedures and high-quality experts providing the
treatment limits the degree to which these results can be
generalized. Furthermore, controlling compliance and
adherence represents elements of efficacy. However, this
is the first ‘head-to head’ comparison in the West, where
Ayurveda is mainly known as wellness intervention; it is
useful to run a smaller trial in a more controlled envir-
onment before starting a large multicenter trial.
Effectiveness trials on traditional medical systems obvi-
ously have to deal with difficulties based on system-
dependent aspects of nomenclature, approaches, and para-
digms. Future trials have to consider this and should try to
incorporate both approaches into the study designs, to
allow a better comparison of the systems involved. Ac-
cordingly, future trial methodology in this field cannot
merely follow typical clinical drug trial methodology (‘one
treatment fits all patients’), but should use an innovative
approach and take traditional aspects from a whole-
medical-system perspective into account, without at the
same time violating the principles of evidence-based medi-
cine research.
For future research on Ayurveda, designs that allow more
flexible interventions from a whole-systems Ayurvedic
approach perspective (for example, dynamic principles, in-
dividuality and a tailored treatment approach, the concept
of constitution, the milieu interior concept, and a focus on
prevention and salutogenesis) should be tested.Trial status
The study is recruiting patients.
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